Trial Profile
Feasibility study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced biliary tract cancer with carcinomatous ascites.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 May 2022
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel; Paclitaxel
- Indications Biliary cancer
- Focus Therapeutic Use
- 19 May 2022 Status changed from recruiting to discontinued.
- 27 Mar 2012 New trial record